Group 1 - AI-driven drug development has made significant progress, with a clinical concept validation result published in Nature Medicine [1][2] - The drug Rentosertib, developed using generative AI platform Pharma.AI, shows preliminary safety and efficacy in a Phase IIa clinical trial for idiopathic pulmonary fibrosis [2][3] - The AI approach allows for broader exploration of drug targets and pathways compared to traditional methods, enhancing efficiency and cost-effectiveness [3] Group 2 - The global AI pharmaceutical market reached $1.04 billion in 2022 and is projected to grow to nearly $3 billion by 2026, with a compound annual growth rate of 30% [3] - In China, the release of guidelines and policies is expected to drive the explosive growth of the "AI + healthcare" industry, with a focus on digital transformation in the pharmaceutical sector by 2030 [4][5]
中新健康丨AI制药迎新进展，能否颠覆传统研发？
Huan Qiu Wang Zi Xun·2025-06-10 10:40